Search by Drug Name or NDC
NDC 50090-3372-00 Shingrix Details
Shingrix
Shingrix is a KIT in the VACCINE category. It is labeled and distributed by A-S Medication Solutions. The primary component is .
MedlinePlus Drug Summary
Why get vaccinated? Recombinant zoster (shingles) vaccine can prevent shingles. Shingles (also called herpes zoster, or just zoster) is a painful skin rash, usually with blisters. In addition to the rash, shingles can cause fever, headache, chills, or upset stomach. More rarely, shingles can lead to pneumonia, hearing problems, blindness, brain inflammation (encephalitis), or death. The most common complication of shingles is long-term nerve pain called postherpetic neuralgia (PHN). PHN occurs in the areas where the shingles rash was, even after the rash clears up. It can last for months or years after the rash goes away. The pain from PHN can be severe and debilitating. About 10 to 18% of people who get shingles will experience PHN. The risk of PHN increases with age. An older adult with shingles is more likely to develop PHN and have longer lasting and more severe pain than a younger person with shingles. Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body and can cause shingles later in life. Shingles cannot be passed from one person to another, but the virus that causes shingles can spread and cause chickenpox in someone who had never had chickenpox or received chickenpox vaccine.
Related Packages: 50090-3372-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Recombinant Zoster (Shingles) Vaccine (RZV)
Product Information
NDC | 50090-3372 |
---|---|
Product ID | 50090-3372_6f4fbb1a-709b-4f96-86de-4ff86fbb30c2 |
Associated GPIs | 17100095401920 |
GCN Sequence Number | 077837 |
GCN Sequence Number Description | varicella-zoster gE/AS01B/PF KIT 50 MCG/0.5 INTRAMUSC |
HIC3 | W7B |
HIC3 Description | VIRAL/TUMORIGENIC VACCINES |
GCN | 43989 |
HICL Sequence Number | 044582 |
HICL Sequence Number Description | VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E,REC/AS01B ADJUVANT/PF |
Brand/Generic | Generic |
Proprietary Name | Shingrix |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Zoster Vaccine Recombinant, Adjuvanted |
Product Type | VACCINE |
Dosage Form | KIT |
Route | n/a |
Active Ingredient Strength | n/a |
Active Ingredient Units | n/a |
Substance Name | n/a |
Labeler Name | A-S Medication Solutions |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125614 |
Listing Certified Through | 2025-12-31 |
Package
NDC 50090-3372-00 (50090337200)
NDC Package Code | 50090-3372-0 |
---|---|
Billing NDC | 50090337200 |
Package | 1 KIT in 1 KIT (50090-3372-0) * .5 mL in 1 VIAL (58160-828-03) * .5 mL in 1 VIAL (58160-829-03) |
Marketing Start Date | 2017-10-20 |
NDC Exclude Flag | N |
Pricing Information | N/A |